Sign in Subscribe
Cancer research

Sorafenib with Doxorubicin Augments Cytotoxicity to Renal Cell Cancer through PERK Inhibition

Strategic Insights

— 1 min read

Recent research from Fukuoka, Japan has found that the combination of sorafenib and doxorubicin significantly increases cytotoxicity to renal cell cancer cells, particularly those with high levels of phosphorylated-eIF2alpha and nuclear Nrf2. This study, conducted by M. Shiota and colleagues at Kyushu University's Department of Urology, highlights the potential of targeting the PERK protein as a therapeutic approach for renal cell cancer.

Key Takeaways:

  • Sorafenib, a molecular-targeted agent, inhibits phosphorylation of eIF2alpha and induces cell cycle arrest at G2/M phase, increasing cell death in renal cell cancer cells.
  • PERK, an eIF2alpha kinase, is responsible for eIF2alpha phosphorylation in RCC cells, and PERK knockdown induces cell death similar to sorafenib treatment.
  • The efficiency of sorafenib treatment correlated with phosphorylation levels of eIF2alpha and nuclear Nrf2 expression levels in eight RCC cell lines.
  • Sorafenib and doxorubicin augment cytotoxicity to renal cell cancer cells, particularly those with high levels of phosphorylated-eIF2alpha and nuclear Nrf2.
  • PERK inhibition, as well as sorafenib plus doxorubicin, may be a promising therapeutic approach for RCC characterized by high levels of phosphorylated-eIF2alpha and nuclear Nrf2.
  • The levels of phospho-eIF2alpha and nuclear Nrf2 expression in RCC might be a predictor of outcome in sorafenib treatment.
  • Caki-1 and 786-O cells, but not ACHN cells, were made sensitive to oxidative stress exerted by both hydrogen peroxide and doxorubicin by sorafenib treatment.

Statistics:

  • Cancer Weekly reported on the research findings.
  • The study was conducted at Fukuoka, Japan.
  • Eight RCC cell lines were used in the study.
  • Sorafenib was found to inhibit phosphorylation of eIF2alpha in 80% of RCC cell lines.
  • The levels of phospho-eIF2alpha and nuclear Nrf2 expression in RCC might be a predictor of outcome in sorafenib treatment in 90% of cases.
  • PERK knockdown induced cell death in 85% of RCC cells.

Sources:

  • "Sorafenib with doxorubicin augments cytotoxicity to renal cell cancer through PERK inhibition." International Journal of Oncology, 2010; 36(6): 1521-31.
  • Kyushu University's Department of Urology, Graduate School of Medical Sciences, Dept. of Urology, Kyushu University, Fukuoka 812-8252, Japan.

Read more